2ESSB 5594: Concerning biosimilar medicines. (REVISED FOR ENGROSSED: Concerning biosimilar medicines and interchangeable biological products.)
Did not pass. The 2025-26 session has ended.
- Sponsor
- Harris
- Introduced
- January 30, 2025
- Status
- S Rules 3
- Last action
- By resolution, returned to Senate Rules Committee for third reading. (March 12, 2026)
- As of
- October 16, 2026, 5:15 AM Pacific, from the Legislature’s records
What this bill does
Authorizes a health carrier or prescription drug utilization management entity to require a patient to try a biosimilar prior to providing coverage for the equivalent branded drug. Modifies provisions authorizing the substitution of therapeutically equivalent drugs or interchangeable biological products by pharmacists.
From the Washington State Legislature's nonpartisan staff bill analysis. Read the full analysis ↗
Floor votes
- Senate: 3rd Reading & Final Passage · March 11, 202549 yea · 0 nay
- Senate: 3rd Reading & Final Passage · January 21, 202649 yea · 0 nay
Track 2ESSB 5594 on OlympiaTrack
A free account adds the full hearing and amendment record, who testified, roll calls by member, and a list to track it on. Paid plans add a plain-English AI summary and an alert if its subject comes back next session.
Create a free accountOther bills sponsored by Harris
- SSB 5316: Modifying provisions of the revised uniform unclaimed property act.
- SSB 5370: Lengthening port commissioner terms.
- SB 5455: Concerning the administration of the Andy Hill cancer research endowment.
- ESSB 5628: Concerning lead in cookware.
- ESSB 5629: Concerning coverage requirements for prosthetic limbs and custom orthotic braces.
All 2025-26 Washington State bills →
Source: the Washington State Legislature. OlympiaTrack is an independent bill-tracking service and is not affiliated with the Legislature. View on leg.wa.gov ↗